Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Peter Clark, MA, MD, FRCP: A Payer Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement




Mar
20
Today In Oncology
FDA Approves Chemoimmunotherapy Regimen for Hodgkin Lymphoma
Hypofractionated Locoregional RT in Early Breast Cancer
Melanoma-Specific Survival With Sentinel Lymph Node Biopsy
Breast Cancer Ultrasensitive ctDNA Assay Findings and Outcomes After Neoadjuvant Therapy
AMA Survey Finds Rapid Growth in Physician AI Adoption
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo